These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 9627740)
41. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder. Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341 [TBL] [Abstract][Full Text] [Related]
42. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study. Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962 [TBL] [Abstract][Full Text] [Related]
44. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. McGrath JJ; Soares KV Cochrane Database Syst Rev; 2000; (2):CD000459. PubMed ID: 10796546 [TBL] [Abstract][Full Text] [Related]
45. Clinical effectiveness of the Kampo medicine kamishoyosan for adjunctive treatment of tardive dyskinesia in patients with schizophrenia: a 16-week open trial. Lee JG; Shin BS; Lee YC; Park SW; Kim YH Psychiatry Clin Neurosci; 2007 Oct; 61(5):509-14. PubMed ID: 17875029 [TBL] [Abstract][Full Text] [Related]
46. The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder. McIntyre RS; Calabrese JR; Nierenberg AA; Farahmand K; Yonan C; Siegert S; Burke J J Affect Disord; 2019 Mar; 246():217-223. PubMed ID: 30583148 [TBL] [Abstract][Full Text] [Related]
47. Switching antipsychotic treatment to aripiprazole in psychotic patients with neuroleptic-induced tardive dyskinesia: a 24-week follow-up study. Chan CH; Chan HY; Chen YC Int Clin Psychopharmacol; 2018 May; 33(3):155-162. PubMed ID: 29324468 [TBL] [Abstract][Full Text] [Related]
48. Extract of Ginkgo biloba is equivalent to vitamin E in attenuating and preventing vacuous chewing movements in a rat model of tardive dyskinesia. An HM; Tan YL; Shi J; Wang ZR; Li J; Wang YC; Kosten TR; Zhou DF; Yang FD; Zhang XY Behav Pharmacol; 2013 Oct; 24(7):610-6. PubMed ID: 23994817 [TBL] [Abstract][Full Text] [Related]
49. Ginkgo biloba leaf extract and alpha-tocopherol attenuate haloperidol-induced orofacial dyskinesia in rats: Possible implication of antiapoptotic mechanisms by preventing Bcl-2 decrease and Bax elevation. An HM; Tan YL; Shi J; Wang Z; Lv MH; Soares JC; Zhou D; Yang F; Zhang XY Phytomedicine; 2016 Dec; 23(13):1653-1660. PubMed ID: 27823630 [TBL] [Abstract][Full Text] [Related]
50. Use of aripiprazole in tardive dyskinesia: an open label study of six cases. Rajarethinam R; Dziuba J; Manji S; Pizzuti A; Lachover L; Keshavan M World J Biol Psychiatry; 2009; 10(4 Pt 2):416-9. PubMed ID: 19492247 [TBL] [Abstract][Full Text] [Related]
51. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Anderson KE; Stamler D; Davis MD; Factor SA; Hauser RA; Isojärvi J; Jarskog LF; Jimenez-Shahed J; Kumar R; McEvoy JP; Ochudlo S; Ondo WG; Fernandez HH Lancet Psychiatry; 2017 Aug; 4(8):595-604. PubMed ID: 28668671 [TBL] [Abstract][Full Text] [Related]
52. Tardive dyskinesia: review of treatments past, present, and future. Gupta S; Mosnik D; Black DW; Berry S; Masand PS Ann Clin Psychiatry; 1999 Dec; 11(4):257-66. PubMed ID: 10596740 [TBL] [Abstract][Full Text] [Related]
54. Severe tardive dyskinesia in affective disorders: treatment with vitamin E and C. Michael N; Sourgens H; Arolt V; Erfurth A Neuropsychobiology; 2002; 46 Suppl 1():28-30. PubMed ID: 12571430 [TBL] [Abstract][Full Text] [Related]
55. Stable remission of tardive dyskinesia by L-dopa. Ludatscher JI J Clin Psychopharmacol; 1989 Feb; 9(1):39-41. PubMed ID: 2565346 [TBL] [Abstract][Full Text] [Related]
56. Reliability of an instrumental assessment of tardive dyskinesia: results from VA Cooperative Study #394. Caligiuri MP; Lohr JB; Rotrosen J; Adler L; Lavori P; Edson R; Tracy K Psychopharmacology (Berl); 1997 Jul; 132(1):61-6. PubMed ID: 9272760 [TBL] [Abstract][Full Text] [Related]
58. Whither vitamin E and tardive dyskinesia? Lohr JB; Lavori P Biol Psychiatry; 1998 Jun; 43(12):861-2. PubMed ID: 9627738 [No Abstract] [Full Text] [Related]
59. Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E. Cadet JL; Lohr JB Ann N Y Acad Sci; 1989; 570():176-85. PubMed ID: 2576510 [No Abstract] [Full Text] [Related]
60. Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment. Peet M; Laugharne J; Rangarajan N; Reynolds GP Int Clin Psychopharmacol; 1993; 8(3):151-3. PubMed ID: 8263312 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]